Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | RGS12 | O14924 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | THPO | P40225 | 1/20 | 0.48 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL26653709 | 1.00 | ADRA2C (0.48) | ADRA2CCHRM2ADRA1ARGS12GLA | |
| SCHEMBL26858844 | 0.98 | ADRA2C (0.50) | ADRA2CCHRM2ADRA1ARGS12GLA | |
| Bromide SCHEMBL6005252 | 0.85 | ADRA2C (0.48) | ADRA2CCHRM2ADRA1ARGS12GLA | |
| Bromide SCHEMBL3676829 | 0.82 | CYP2D6 (0.46) | ADRA2CCHRM2ADRA1ARGS12GLA | |
| Bromide SCHEMBL3571270 | 0.80 | ASAH1 (0.51) | ADRA2CCHRM2ADRA1ARGS12GLA | |
| Bromide SCHEMBL29992023 | 0.80 | ASAH1 (0.51) | ADRA2CCHRM2ADRA1ARGS12GLA | |
| Bromide SCHEMBL5598421 | 0.80 | ASAH1 (0.51) | ADRA2CCHRM2ADRA1ARGS12GLA | |
| Bromide SCHEMBL306447 | 0.80 | ADRA2C (0.55) | ADRA2CCHRM2ADRA1ARGS12GLA | |
| SCHEMBL7900506 | 0.80 | CYP2D6 (0.47) | ADRA2CCHRM2ADRA1ARGS12GLA | |
| SCHEMBL3569539 | 0.80 | CYP2D6 (0.47) | ADRA2CCHRM2ADRA1ARGS12GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552808-B2 | Diol desymmetrization by nucleophilic aromatic substitution | AMGEN INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20230365588-A1 | DIOL DESYMMETRIZATION BY NUCLEOPHILIC AROMATIC SUBSTITUTION | AMGEN INC. (US) | 2023-11-16 | — | — | US | disclosed |
| EP-4208467-A1 | DIOL DESYMMETRIZATION BY NUCLEOPHILIC AROMATIC SUBSTITUTION | Amgen Inc. (US) | 2023-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552808-B2 | Diol desymmetrization by nucleophilic aromatic substitution | MCL1, BAK1, BCL2 | CHRM2 3010/4885ADRA2C 2358/4885ADRA1A 879/4885 |
| US-20230365588-A1 | DIOL DESYMMETRIZATION BY NUCLEOPHILIC AROMATIC SUBSTITUTION | MCL1, BAK1, BCL2A1 | CHRM2 4648/4885ADRA2C 3450/4885ADRA1A 1321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.